India healthcare: Nomura expects a healthy Q4

Ipca Laboratories

10/04/2019 05:21

** Nomura expects a healthy Q4 for Indian healthcare and
pharmaceuticals sector
    ** It sees revenue growth at 11 pct year-on-year in Q4;
EBITDA and net earnings likely to witness record growth of 17
pct and 8 pct, respectively
    ** Prescription volumes have increased for most India
companies year-on-year as they gained market share, Nomura said
in a note
    ** Brokerage expects mid-teens growth in revenues for
diagnostics sector and steady improvement quarter-on-quarter in
volumes and EBITDA margins for hospitals
    ** Lupin Ltd  LUPN.NS , IPCA Laboratories Ltd  IPCA.NS ,
Apollo Hospitals Enterprise Ltd  APLH.NS  could see investors’
interest in the near term as we expect their results/outlook
commentaries to surprise the street on the upside - Nomura
    ** The Nifty Pharma Index  .NIPHARM  up 0.26 pct in early
trading on Wednesday; up 5.24 pct this year as of last close

 ((harish.bhaskar.thomsonreuters.com@reuters.net))